- Approximately 50% of patients who have bladder cancer will see a recurrence of the condition – often due to poor margin visibility
- White light has been the standard procedure during cystoscopies, but is only beneficial if tumors protrude from the bladder wall
- Blue light cystoscopies address this issue, increasing the odds of removing more cancerous cells and reducing the recurrence of the cancer
- The i/Blue Imaging System(TM) improves surgical technique by combining both white and blue light capabilities on one screen without the necessity of switching between two images
- Imagin Medical Inc. is currently moving toward commercializing the system, expecting to complete the product in 2022
Approximately 50% of patients who suffer from non-muscle-invasive bladder cancer will relapse. Even with the rates of local recurrence after definitive therapy improving, research indicates that management of the disease remains a challenge. Urothelial carcinoma, the most common type of bladder cancer, continues to exhibit high rates of recurrence (https://ibn.fm/4HXcP).
The primary treatment for recurrence focuses on cytology, stage, and clinical characteristics. A particular area of interest is identification and causes/predictors of urothelial carcinoma recurrence. Differentiating management of recurrent carcinoma from treatment of primary carcinoma has…
NOTE TO INVESTORS: The latest news and updates relating to IMEXF are available in the company’s newsroom at https://ibn.fm/IMEXF
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.